In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…
Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…